Methylated DNA Markers for Detection of Neoplasia: Novel Approaches are Accurate and Site-specific
DCEG Events
February 2, 2017 | 9:30 AM – 10:30 AM
NCI Shady Grove Rockville, Maryland
Speakers
David Ahlquist, M.D.
Consultant, Division of Gastroenterology & Hepatology, Professor of Medicine, and the Carol M. Gatton Professor of Digestive Diseases Research
Mayo Clinic (Rochester, Minnesota)
Dr. Ahlquist has held numerous leadership positions at Mayo Clinic and in professional societies. Dr. Ahlquist is internationally recognized for his research in the early detection of colorectal and other gastrointestinal neoplasms. He has received research career achievement awards at Mayo Clinic and nationally (William Beaumont Prize at AGA). He and his team co-developed a stool DNA test for colorectal cancer screening that was recently approved by FDA and is now available commercially (Cologuard). The scope of his research has expanded to encompass the most prevalent cancers across all organ systems and continues to focus on the development and validation of molecular screening tools which are noninvasive, accurate, and user-friendly. Dr. Ahlquist has mentored more than 50 residents and fellows in his research program. He has published extensively and holds numerous patents related to his work.
Graham P. Lidgard, Ph.D.
Chief Science Officer and Senior Vice President Research & Development
Exact Sciences
Dr. Lidgard oversees the research and product development organization for Exact Sciences. Prior to 2009, Dr. Ligard was the senior vice president of research and development for Nanogen, Inc.; vice president research and development for Gen-Probe Inc.; co-founder and vice president of product development for Matritech, Inc.; and worked at Ciba Corning Diagnostics Corp. He received his Ph.D. and B.Sc. (Honors) from the University of Manchester, England.
Host
Charles Rabkin, M.D., senior investigator, Infections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute